	US 11,884,735 B2
	Agonistic anti-IL-2R antibodies and methods of use
Nathan Trinklein, Redwood City, CA (US); Katherine Harris, Fremont, CA (US); Kyle Lorentsen, Dublin, CA (US); Harbani Kaur Malik Chaudhry, Oakland, CA (US); and Kaitlyn Loughlin, San Mateo, CA (US)
Assigned to TENEOBIO, INC., Thousand Oaks, CA (US)
Filed by TeneoBio, Inc., Thousand Oaks, CA (US)
Filed on Feb. 3, 2023, as Appl. No. 18/164,442.
Application 18/164,442 is a continuation of application No. PCT/US2022/023058, filed on Apr. 1, 2022.
Claims priority of provisional application 63/239,883, filed on Sep. 1, 2021.
Claims priority of provisional application 63/170,383, filed on Apr. 2, 2021.
Prior Publication US 2023/0242653 A1, Aug. 3, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/62 (2013.01); C07K 2317/75 (2013.01)]

25 Claims

1. A heavy chain-only antibody comprising:

a first heavy chain variable region that binds to IL2RB, comprising:

a CDR1 sequence comprising the formula:

G G S I S S S X1 W (SEQ ID NO: 26)

wherein X1 is D or N; and

a CDR2 sequence comprising the formula:

I X2 H S G S T (SEQ ID NO: 27)

wherein X2 is D or S; and

a CDR3 sequence comprising the formula:

X3 R G X4 W E L X5 D A F D I (SEQ ID NO: 28)

wherein X3 is G or A;

X4 is S or Q; and

X5 is S or T; and

a second heavy chain variable region that binds to IL2RG, comprising:

a CDR1 sequence comprising the formula:

G F X1 X2 X3 X4 Y Y (SEQ ID NO: 32)

wherein X1 is T or I;

X2 is F or V;

X3 is S, N, or G; and

X4 is D or N; and

a CDR2 sequence comprising the formula:

I S X5 S G X6 X7 I (SEQ ID NO: 33)

wherein X5 is S or N;

X6 is D, S, G, or N; and

X7 is T or I; and

a CDR3 sequence comprising the sequence ARGDAVSITGDY (SEQ ID NO: 20).